- Vivir con FSHD
-
- Participa
-
- Investigación y asistencia clínica
- Quiénes somos
- Noticias y medios de comunicación
- Eventos
- Blog
- BetterLife
- Donar hoy
We can change the future of FSHD. Double your impact while matching funds last!
Here are the agenda, speaker biographies, and presentation materials from our Miami FSHD Family Day Conference, which was held on Saturday, February 23, 2019, at the beautiful Newman Alumni Center at the University of Miami in Coral Gables. Click on the talk titles to download the slides.
Best practices in caring for FSHD
• FSHD 101 – What every patient needs to know. Mario Saporta, MD PhD MBA, is an Assistant Professor of Neurology and Human Genetics at the University of Miami. He is the director of the Muscular Dystrophy Association Care Center and Charcot-Marie-Tooth Center of Excellence at the University of Miami where he coordinates a multidisciplinary team providing specialized care for patients with neuromuscular genetic disorders. He is also a principal investigator leading a research group focused on the use of human stem cells to study neuromuscular genetic conditions. He will review the basics of FSHD and provide an update on the current clinical trials for FSHD
• FSHD Genetics: Everything you want to know (plus some more). Stephanie Bivona, MS, CGC, is a board-certified genetic counselor who specializes in neurogenetics. She is the genetic counselor for the Muscular Dystrophy Association clinic at the University of Miami. She will be discussing the role of a genetic counselor for families with FSHD, genetic causes of FSHD, and genetic testing for FSHD.
• FSHD and Physical Therapy Implications. Kayla Chomko, DPT, received her bachelor’s degree from the University of Florida in 2005 in the area of Health Science and earned her doctor of physical therapy degree from the University of Miami in 2008. Since graduation, Dr. Chomko has focused on the treatment of neurological disorders, specifically working with patients and loved ones affected by neurodegenerative diseases. Kayla is the lead physical therapist within the Neurology department with a focus on muscular dystrophies, ALS and CMT among many other neurological conditions. She joined University of Miami Department of Physical Therapy as voluntary adjunct assistant professor and is assisting with establishing their Neurological Residency program. Kayla is eager to educate the community regarding how physical therapy can assist patients with FSHD and best practices within the field regarding this diagnosis.
Advances in FSHD treatments
• FSHD Clinical Trials. Mario Saporta, MD PhD MBA. See biography above.
• The Future of FSHD Therapies. Peter Jones, PhD, is the Mick Hitchcock Endowed Chair of Medical Biochemistry and Associate Professor of Pharmacology at the University of Nevada, Reno School of Medicine. He earned a bachelor’s degree in microbiology from Miami University in Oxford, OH, and then his PhD in genetics and molecular biology at Emory University School of Medicine in Atlanta, GA. He went on to a post-doctoral fellowship at the National Institutes of Health, Bethesda, MD, where he expanded his training into biochemistry, chromatin and epigenetics. Since 2003, Dr. Jones’ lab has been investigating epigenetic dysregulation underlying FSHD pathogenesis to identify therapeutic targets, develop more affordable and accessible diagnostics, and aid in the generation of cell and animal models of the disease for better therapeutic development and pre-clinical testing. He currently runs the lab with his wife and Co-PI, Dr. Takako Jones.
• An Engaged and Empowered Community. June Kinoshita, is Chief Strategic Programs Officer at the FSH Society. She joined the Society in 2012. Her focus is on the intersection of patient engagement and therapy development. As part of the Society’s research team, she works closely with academic and industry partners on the Therapeutic Accelerator project. She organizes FSHD Family Day conferences across the U.S. as well as the annual FSHD International Research Congress. June is also Editor of the FSHD Advocate and the FSH Society’s educational publications, website and social media content.